Lamotrigine Patent Expiration
Lamotrigine was first introduced by Glaxosmithkline Llc
Lamotrigine Patents
Given below is the list of patents protecting Lamotrigine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Subvenite | US11596634 | Lamotrigine Oral Liquid Suspension And Use Thereof | May 29, 2040 | Owp Pharms |
| Subvenite | US11612566 | Lamotrigine Oral Liquid Suspension And Use Thereof | May 29, 2040 | Owp Pharms |
| Subvenite | US12629377 | Lamotrigine Oral Liquid Suspension And Use Thereof | May 29, 2040 | Owp Pharms |
| Subvenite | US12636289 | Lamotrigine Oral Liquid Suspension And Use Thereof | May 29, 2040 | Owp Pharms |
| Lamictal Xr | US8637512 | Formulations and method of treatment | Jan 07, 2029 | Glaxosmithkline Llc |
| Lamictal Odt | US7919115 | Orally disintegrating tablet compositions of lamotrigine | Jan 04, 2029 | Glaxosmithkline Llc |
| Lamictal Odt | US8840925 | Orally disintegrating tablet compositions of lamotrigine | Jul 02, 2028 | Glaxosmithkline Llc |
| Lamictal Odt | US9339504 | Orally disintegrating tablet compositions of lamotrigine | Jul 02, 2028 | Glaxosmithkline Llc |
| Lamictal Xr | US9144547 | Oral dosage form for controlled drug release |
Sep 22, 2023
(Expired) | Glaxosmithkline Llc |
| Lamictal Cd |
US5698226 (Pediatric) | Water-dispersible tablets |
Jul 29, 2012
(Expired) | Glaxosmithkline Llc |
Lamotrigine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lamotrigine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression | University Health Network, Toronto | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder | Lakshmi N Yatham | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |